II. Indications
- 
                          Alzheimer's Disease
                          - Increased Cholinergic Activity by Anticholinesterases crossing the blood brain barrier may reduce Dementia related symptoms
- Central Cholinesterase Inhibitor examples include Aricept (Donepezil), Rivastigmine (Exelon), Galantamine (Reminyl)
 
- 
                          Glaucoma
                          - Increased Cholinergic Activity the iris sphincter Muscle (Miosis)
- Pupil Constriction pulls the iris away from canal of schlemm, increasing Aqueous Humor outflow (decreases Intraocular Pressure)
 
- 
                          Myasthenia Gravis
                          - Peripheral Anticholinesterases (e.g. neostigmine) prolong Acetylcholine activity at the Neuromuscular Junction
- Overcomes the myasthenia autoantibody binding of Neuromuscular JunctionNicotinic Receptors
 
III. Mechanism
- 
                          Acetylcholine
                          - 
                              Neurotransmitter for autonomic preganglionic Neuron Synapses (CNS to autonomic Ganglion)- Acetylcholine mediates both preganglionic sympathetic and Parasympathetic Systems
 
- 
                              Acetylcholine is Neurotransmitter for parasympathetic postganglionic Neurons (autonomic Ganglion to target organ)- Acts at muscarinic and nictonic Acetylcholine receptors
 
- 
                              Acetylcholine is the Neurotransmitter at the Neuromuscular Junction- Muscle Contraction is triggered by release of Acetylcholine into the synaptic cleft
 
 
- 
                              Neurotransmitter for autonomic preganglionic Neuron Synapses (CNS to autonomic Ganglion)
- 
                          Acetylcholinesterase- Acetylcholinesterase cleaves and deactivates Acetylcholine at the synaptic cleft, leading to a short AcetylcholineHalf-Life
 
- Cholinesterase Inhibitor (Anticholinesterase)- Inhibit Acetylcholinesterase activity, thereby resulting in prolonged Acetylcholine activity within the Synapse
 
- Images
IV. Types
- Carbamyl Ester Inhibitors- Inhibition of Acetylcholinesterase via competitively binding the Acetylcholine site
- On cleaving the Carbamyl Ester link, Acetylcholinesterase is carbamylated
- Acetylcholinesterase is deactivated for minutes to hours until it is reactivated by decarbamylation
- Examples include agents used in Dementia, Myasthenia Gravis and Glaucoma
 
- Organophosphorus Inhibitors (Organophosphates)- High affinity binding to the Acetylcholine site renders Acetylcholinesterase permanently inactivated
- Acetylcholinesterase must be regenerated over days to weeks to Restore activity at the Synapse
- Examples include OrganophosphatePesticides and Nerve Agents
 
V. Medications: Central Nervous System Agents
- Central Cholinesterase Inhibitor for Dementia Management
- 
                          Physostigmine
                          - Carbamyl Ester Inhibitor administered IM/IV for reversal of AnticholinergicOverdose
 
VI. Medications: Peripheral Nervous System Agents (Myasthenia Gravis)
- Neostigmine (Prostigmine)
- Pyridostigmine (Mestinon)
- Ambenonium (Mytelase)- Prolonged activity
 
VII. Medications: Ocular Topical Agents (Glaucoma)
- See Intraocular Parasympathomimetic
- Demacarium (Humorsol)
- Echothiophate (Phosphate Iodide)
VIII. References
- Olson (2020) Clinical Pharm, Medmaster, Miami, p. 26-7
 
          
